2 nd ESTRO Forum 2013 S203 chemotherapy to evaluate the rate of second cancers and their sites according to the extension of radiation fields. Materials and Methods : From 1990: From to 1995 with early-stage HL (IA, IB, IIA ± bulky) received 4 cycles of ABVD and then they were randomized to receive STNI (36 Gy to involved sites and 30 Gy to uninvolved sites) or IF (36 Gy to involved sites). The endpoints of this review were to assess the rate of late toxicity in term of SPC and the spatial relationship between radiation fields extent and SPC. We used the topographical criteria defined by Dorr 1 to localize SPC compared to RT fields. Event-free survival (EFS) and overall survival (OS) were estimated by Kaplan-Meier method. Crude and age-adjusted incidence rates of SPC were calculated by Poisson regression. Results: After a median follow-up of 203 months, 24 SPC were observed: 7 cutaneous basal cell carcinomas, 1 MDS, 16 solid tumours (11 breast, 2 prostate, 1 ovary, 1 skin, 1 colon) . For this study we evaluated only solid cancers. 13 SPC were in STNI arm, 3 in IFRT (p 0.014). Median time to second malignancies was 172 months in STNI and 178 in IFRT. IR (incidence rate/1000 person-years) 12.9 in STNI and 2.76 in IFRT (p 0.014). In a univariate analysis, the second malignancies risk is higher in STNI versus IFRT (hazard ratio 4.40, 95% CI). According to the topographic criteria, SPC were located as listed below:
In-field Margin Adjacent Distant Breast 8 3 0 0 Other 0 0 2 3 Dose at in-field region was 36 Gy in all cases. Median age at breast cancer diagnosis was 43years (27y at HL diagnosis); median age at diagnosis of other cancers was 62y (49y at HL diagnosis). 7 breast cancers (5 infiltrating carcinoma and 2 in situ) were treated with conservative surgery and in 5 cases radiationtherapy was performed. 2 breast cancer pts died (1 myocardial infarction, 1 disease progression). All the remaining pts are alive and with no evidence of both tumours. Conclusions: Combined modality treatment is currently the treatment of choice for early-stage HL. In this setting of patients, RT contributes to achieving a high cure-rate. Despite the fact that the optimal size of RT fields and dose are still unknown, our data confirm that reducing of field size to IF is safe both in terms of cure rate and reduction of second cancers. Purpose/Objective: Glioblastoma multiforme (GBM) is the most aggressive type of brain cancer in adults. It is suggested that tumour microenvironment might influence treatment outcome of cancer patients. The aim of this study was to evaluate the impact of inflammation on treatment response and survival of GBM patients. Materials and Methods: Between Jan 2006 and Dec 2008, 42 patients were operated and received postoperative radiotherapy (±chemotherapy). Surgically excised GBM tissues were immunohistochemically examined for CD63 expression. Since CD63 is expressed on inflammatory cells (monocytes, macrophages, granulocytes), the number of CD63-positive (CD63+) cells per microscopic field was determined. Also, haematoxylin-eosin stained tumour sections were histologically examined for overall proportion of necrosis (%) and microvascular proliferations (MP; low, medium, high). Finally, CD63 expression was correlated with patients overall survival. Results: Immunohistochemical parameters were examined by 2 independent researchers whose results were in good accordance (R=0.8, p<0.0001). The number of CD63+ inflammatory cells per microscopic field was 62.1±23.1 (mean±SD). A significant association was found between the number of CD63+ cells and the proportion of necrosis (p=0.004). Also, a correlation between the number of CD63+ cells and the proportion of MP was detected (p=0.009). Median survival time of the study group was 10.0 months (95% CI 9.0-11.0). However, the survival time clearly depended on the number of CD63+ cells in GBM tissue (log rank test, p=0.003). Median survival times for patients with low (less than median) and high (equal or more than median) number of CD63+ cells were 9.0 months (95% CI 8.1-9.9) and 12.0 months (95% CI 8.5-15.5) respectively. In multivariate analysis, the number of CD63+ cells emerged as a significant independent predictor for longer overall survival (HR 2.4, 95% CI 1.2-5.1, p=0.02). Conclusions: Present study revealed a beneficial role of inflammation on survival of GBM patients. In patients with higher number of CD63+ cells prior radiotherapy, significantly longer survival times were achieved. Additionally, inflammatory reaction was associated with tumour micromilieu: there were more inflammatory cells in the presence of high proportion of necrosis and MP. Clearly, more studies are needed to evaluate the role of inflammation and tumour microenvironment on GBM treatment outcome. This work was supported by Institutional Research Funding
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An update on re-irradiation and bevacizumab in recurrent highgrade glioma M. Niyazi 1 , M.C. Flieger 1 , U. Ganswindt 1 , S.B. Schwarz 1 , F.W. Kreth 2 , J.C. Tonn 2 , C. la Fougère 3 , L. Ertl 4 , J. Linn 4 , C. Belka 1 Purpose/Objective: Re-irradiation has been shown to be an option for recurrent high-grade glioma patients with proven but limited efficacy. Furthermore, bevacizumab exerts certain efficacy in combination with chemotherapy or as monotherapy and was safely tested in combination with radiotherapy for re-treatment in smaller studies. This report gives an update on the outcome of patients treated at the University hospital of Munich. To our knowledge, this is the largest cohort including patients treated with both re-irradiation and bevacizumab to date. Materials and Methods: After receiving standard radiotherapy (with or without TMZ) patients with recurrent malignant glioma were treated with bevacizumab (10mg/kg intravenously at d1 and d15) during reirradiation. Median prescribed radiation dose during re-treatment was 36Gy, conventionally fractionated. Results: 71 patients re-irradiated in a single institution were retrospectively analyzed. Patients either received bevacizumab (N=57), other substances (N=4) or radiation alone (N=10). Reirradiation was tolerated well regardless of the additional therapy. In one patient with bevacizumab a wound dehiscence occurred, one patient suffered from deep vein thrombosis resulting in pulmonary embolism. One patient died of a perforated sigma diverticulitis. Postrecurrence survival was significantly increased in patients receiving bevacizumab (p=0.003, log-rank test) as well as progression-free survival (p=0.005, log-rank test). KPS, surgery, MGMT, sex, WHO grade and age showed no statistically significant improvement in neither PFS nor survival. Conclusions: Re-irradiation with bevacizumab remains a feasible and highly effective treatment schedule. Studies on further salvage strategies and timing of sequential treatment options vs. observation are warranted. Purpose/Objective: In order to define new prognostic subgroups in patients with glioblastoma (GBM) a method is presented how to derive potentially prognostic miRNA patterns employing a large screen (> 1,200 miRNAs) from paraffin tissues including associated methodological problems and pitfalls. Materials and Methods: Thirty-six GBM patients treated in a single institution basically according to the EORTC/NCIC protocol between 1/2009 -12/2010 were included in this retrospective analysis. For microarray analysis, the febit biochip 'Geniom ® Biochip MPEA homo sapiens' was used. Total RNA was isolated from FFPE slides, altogether over 1,200 different miRNAs were analyzed. In order to define significant patterns, a Cox regression analysis for each single miRNA was performed using long-term survival (split at 450 days) as censor; significant miRNAs (without multiple-testing correction) were chosen and a hierarchical clustering analysis was performed; survival of the
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